Eli Lilly LLY and AbbVie ABBV are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Skyrizi and Rinvoq helped AbbVie move beyond Humira, its former top-selling medicine, which lost U.S. patent exclusivity in January 2023. Skyrizi and Rinvoq overlap with many of Humira's ...

Risankizumab (Skyrizi), a selective anti-interleukin-23 (IL-23) biologic agent, is increasingly used in the treatment of Crohn's disease (CD). A previous head-to-head study has demonstrated its ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Bernie Sanders and Angus King introduced a bill that would ban pharmaceutical manufacturers from using direct-to-consumer advertising, including social media, to promote their products.

Skyrizi and Rinvoq helped AbbVie move beyond Humira, its former top-selling medicine, which lost U.S. patent exclusivity in January 2023.

The pharmaceutical industry may find its footing in 2025 as various factors, including President Trump's policies, events such as JPM, and scrutiny from the Federal Trade Commission, shape its future.

ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...